AstraZeneca has decided to withdraw its Covid-19 vaccine globally following months of acknowledging that the drug could result in extremely rare but life-threatening injuries.
The British-Swedish pharmaceutical company has already revoked its EU marketing authorization for the vaccine, known as Vaxzevria since 2021. This authorization allows the drug to be marketed in EU member states. AstraZeneca attributed the withdrawal to the abundance of updated vaccines available against new variants of the coronavirus, leading to decreased demand for Vaxzevria, which is no longer being produced or supplied.
The application to withdraw the vaccine from the EU was submitted on March 5 and took effect on May 7.
AstraZeneca recently acknowledged that its vaccine, initially named Covishield, could lead to very rare side effects such as blood clots and low blood platelet counts. This admission followed a class action lawsuit in the UK, alleging that the vaccine caused deaths and severe injuries and seeking damages of up to £100 million for approximately 50 victims.
The company stated in court documents in February that “It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known,” referring to thrombosis with thrombocytopenia syndrome, characterized by blood clots and low blood platelet counts.
AstraZeneca’s vaccine, developed in collaboration with Oxford University and manufactured by the Serum Institute of India, was widely administered in over 150 countries, including Britain and India.
While some studies conducted during the pandemic found the vaccine to be 60 to 80 percent effective in protecting against the coronavirus, subsequent research revealed its potential to cause fatal blood clots.
AstraZeneca’s acknowledgment that the vaccine could potentially be lethal contradicted its previous stance in 2023 that it would “not accept that TTS is caused by the vaccine at a generic level.”
In April 2021, the World Health Organization also confirmed that the vaccine could have fatal side effects, stating, “A very rare adverse event called thrombosis with thrombocytopenia syndrome, involving unusual and severe blood clotting events associated with low platelet counts, has been reported after vaccination with this vaccine.”
AstraZeneca expressed pride in the role Vaxzevria played in ending the global pandemic, stating, “According to independent estimates, over 6.5 million lives were saved in the first year of use alone, and over three billion doses were supplied globally. Our efforts have been recognized by governments around the world and are widely regarded as being a critical component of ending the global pandemic.”
